logo
Twitter
Discord
Email
logo
The Cooper Companies, Inc.

The Cooper Companies, Inc.

NASDAQ•COO
CEO: Mr. Albert G. White III
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1983-01-21
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Contact Information
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, 94583, United States
925-460-3600
www.coopercos.com
Market Cap
$16.35B
P/E (TTM)
43.4
76.8
Dividend Yield
--
52W High
$100.24
52W Low
$61.78
52W Range
53%
Rank40Top 31.7%
4.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q4 2025 Data

Revenue

$1.07B+4.59%
4-Quarter Trend

EPS

$0.43-27.12%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Months Revenue Growth Nine months net sales reached $3,027.3M, growing 5% compared to $2,877.0M last year period.
Net Income Increased Nine months net income was $290.3M, an increase of 5.6% versus $274.8M previously reported.
Working Capital Improved Working capital improved to $1,127.7M from $928.7M, driven by inventory and receivable increases.
Interest Expense Declining Nine months interest expense decreased 13% to $75.6M due to lower rates and reduced average debt balances.

Risk Factors

IT Control Material Weakness Disclosure controls are not effective due to material weakness in CooperSurgical IT general controls identified.
Segment Operating Loss CooperSurgical Q3 operating income dropped 110% due to inventory write-offs related to product line exit.
Foreign Exchange Exposure Hypothetical 10% currency rate shift impacts quarterly operating income by approximately $26.2M, requiring hedging efforts.
Regulatory Compliance Costs Ongoing compliance costs and potential liability related to evolving health care regulations like MDR and IVDR persist.

Outlook

CooperVision Growth Strategy Optimistic on long-term prospects, focusing on silicone hydrogel expansion and MiSight adoption in myopia management.
Liquidity Position Strong Current cash and $1,369.8M available credit sufficient for anticipated needs including capital expenditures over next 12 months.
Future Capacity Expansion Entered additional leases totaling $181.8M for manufacturing and R&D capacity through fiscal 2026 commencement.
Share Repurchase Authority $163.6M remains authorized for repurchase under the 2012 Share Repurchase Program as of July 31, 2025.

Peer Comparison

Revenue (TTM)

Smith & Nephew plcSNN
$11.61B
+9.9%
Baxter International Inc.BAX
$11.02B
-6.3%
ICON Public Limited CompanyICLR
$8.10B
-2.5%

Gross Margin (Latest Quarter)

Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5pp
Smith & Nephew plcSNN
70.6%
+0.8pp
Illumina, Inc.ILMN
67.6%
-1.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ILMN$20.61B29.930.0%41.7%
WST$19.25B39.317.3%7.4%
HOLX$16.72B29.711.7%27.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.4%
Moderate Growth
4Q Net Income CAGR
-6.7%
Declining Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:$1.02
|
Revenue:-
Reports
All Years
  • Form 10-K - FY 2025

    Period End: Oct 31, 2025|Filed: Dec 5, 2025|
    Revenue: $4.09B+5.1%
    |
    EPS: $1.87-5.1%
    Beat
  • Form 10-Q - Q3 2025

    Period End: Jul 31, 2025|Filed: Aug 28, 2025|
    Revenue: $1.06B+5.7%
    |
    EPS: $0.49-7.5%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Apr 30, 2025|Filed: May 30, 2025|
    Revenue: $1.00B+6.3%
    |
    EPS: $0.44-2.5%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Jan 31, 2025|Filed: Mar 7, 2025|
    Revenue: $964.70M+3.6%
    |
    EPS: $0.52+26.8%
    Miss
  • Form 10-K - FY 2024

    Period End: Oct 31, 2024|Filed: Dec 6, 2024|
    Revenue: $3.90B+8.4%
    |
    EPS: $1.97+32.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Jul 31, 2024|Filed: Aug 29, 2024|
    Revenue: $1.00B+7.8%
    |
    EPS: $0.53+23.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Apr 30, 2024|Filed: May 31, 2024|
    Revenue: $942.60M+7.4%
    |
    EPS: $0.45+125.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Jan 31, 2024|Filed: Mar 1, 2024|
    Revenue: $931.60M+8.5%
    |
    EPS: $0.41-4.7%
    Miss